LeMaitre Vascular (NASDAQ:LMAT) Earns Neutral Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research note issued to investors on Tuesday morning, Marketbeat Ratings reports. The firm issued a neutral rating and a $96.00 price target on the medical instruments supplier’s stock. Cantor Fitzgerald also issued estimates for LeMaitre Vascular’s FY2024 earnings at $1.90 EPS.

A number of other brokerages have also commented on LMAT. Barrington Research reiterated an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a report on Friday, September 20th. JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Finally, Lake Street Capital started coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $94.67.

LeMaitre Vascular Stock Up 0.2 %

LMAT stock opened at $89.88 on Tuesday. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $93.32. The stock’s 50 day moving average is $88.90 and its 200-day moving average is $81.35. The firm has a market capitalization of $2.02 billion, a PE ratio of 59.52, a P/E/G ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company had revenue of $55.85 million for the quarter, compared to analyst estimates of $54.98 million. During the same quarter last year, the company earned $0.37 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.71%. The ex-dividend date of this dividend was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is currently 42.38%.

Insiders Place Their Bets

In other news, Director David B. Roberts sold 3,063 shares of LeMaitre Vascular stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the transaction, the director now directly owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 10.79% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Hedge funds have recently made changes to their positions in the stock. NBC Securities Inc. grew its position in shares of LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 183 shares in the last quarter. GAMMA Investing LLC grew its position in LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 199 shares in the last quarter. West Oak Capital LLC purchased a new position in LeMaitre Vascular during the second quarter worth about $58,000. USA Financial Formulas purchased a new position in LeMaitre Vascular during the third quarter worth about $60,000. Finally, nVerses Capital LLC grew its position in LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock worth $66,000 after buying an additional 200 shares in the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.